Barrett esophagus is a preneoplastic condition defined by the presence of intestinal metaplasia (ie, goblet cells) in an endoscopically apparent columnar-lined esophagus. Dysplasia is the most important risk factor for cancer development among patients with Barrett esophagus; approximately 6% of patients with high-grade dysplasia progress to adenocarcinoma within 1 year. Surgical pathologists are generally expected to address 2 clinical concerns when evaluating mucosal biopsy samples from patients with suspected Barrett esophagus; they should note the presence, or absence, of goblet cells and comment on the grade of dysplasia when it is identified. Biopsy samples from patients with Barrett esophagus are categorized as negative for dysplasia, indefinite for dysplasia, or positive for dysplasia; in the latter situation, the severity of dysplasia is classified as low or high grade. Several histochemical stains, immunohistochemical stains, and molecular techniques can be used to facilitate detection of goblet cells and classify dysplasia in patients with Barrett esophagus, although their added value to routine morphologic assessment is not entirely clear. The purpose of this review is to discuss the state of the art regarding application of ancillary studies to esophageal samples from patients with a columnar-lined esophagus.
B arrett esophagus is characterized by replacement of the squamous lining by glandular mucosa, the latter of which contains variable numbers of goblet and nongoblet mucinous epithelial cells, as well as endocrine cells, Paneth cells, and other cell types. Although the presence of nongoblet foveolar epithelium in samples obtained from endoscopically visible columnar-lined esophagus is sufficient for a diagnosis of Barrett esophagus in some countries, intestinal-type goblet cells are required for this diagnosis in the United States. Available data compel the conclusion that intestinal metaplasia, rather than nongoblet columnar epithelium, is a risk factor for cancer development in the esophagus. Thus, patients in the United States who have esophageal intestinal metaplasia (ie, goblet cells) are encouraged to undergo regular endoscopic surveillance to detect dysplasia, which is the direct precursor of, and single most important risk factor for, esophageal adenocarcinoma. Current recommendations suggest that at least 8 biopsy samples be obtained from endoscopically apparent columnar-lined esophagus, in order to increase the likelihood of identifying goblet cells among patients with suspected Barrett esophagus. Those with an established diagnosis should also undergo extensive mucosal sampling for dysplasia surveillance; gastroenterologists are encouraged to obtain systematic 4-quadrant biopsy samples at 1 to 2 cm intervals throughout the columnar-lined segment, as well as assessment of all endoscopically apparent lesions. 1 Pathologists are generally posed 2 questions when faced with biopsy samples from patients with suspected Barrett esophagus: is intestinal metaplasia identified?; and is dysplasia present? Unfortunately, pathologic evaluation is hampered by several factors. First, nongoblet columnar epithelial cells can simulate goblet cells, leading to an erroneous diagnosis of Barrett esophagus. Second, distinguishing between intestinal metaplasia of the gastric cardia and that of the esophagus may be clinically important for surveillance purposes, yet biopsy samples from these sites commonly show overlapping features that preclude definitive histologic classification. Third, reactive epithelial cell changes mimic dysplasia, especially at the low end of the spectrum where non-neoplastic atypia may be confused with low-grade dysplasia. Finally, grading dysplasia is subject to a relatively high degree of interobserver variability. For these reasons and others, several histochemical, immunohistochemical, and molecular techniques have been applied to samples from patients with suspected, or established Barrett esophagus. The purpose of this review is to summarize existing data regarding the utility of ancillary techniques in the evaluation of patients with Barrett esophagus and/or associated neoplasia.
USE OF ANCILLARY STAINS FOR IDENTIFICATION OF GOBLET CELLS
Biopsy samples from patients with Barrett esophagus usually display goblet cells interspersed among neutral mucin-containing foveolar epithelial cells. Goblet cells are recognizable in routinely stained histologic sections; they contain a large round mucin-filled vacuole that compresses the nucleus. The mucin is acidic, so it usually has a blue-tinge in hematoxylin and eosin (H&E)stained sections (Fig. 1A) . Potential mimics include "pseudogoblet cells" and "columnar blues." Pseudogoblet cells are injured foveolar epithelial cells that contain copious cytoplasmic mucin; these distended cells have a globoid appearance resembling goblet cells, but they are filled with pink cytoplasm similar to that of foveolar epithelium ( Fig. 1B ). Columnar blues are foveolar cells that produce enough acid mucin to impart blue discoloration to the cytoplasm; unlike true goblet cells, they maintain their cylindrical shapes (Fig. 1C ). Multilayered epithelium may also be mistaken for fully developed intestinal metaplasia. It is most commonly seen adjacent to squamous epithelium at the squamocolumnar junction or lining ducts that drain to the mucosal surface. Multilayered epithelium consists of basally located, immature-appearing squamoid cells and superficial clusters of columnar cells that contain acid mucin, similar to that of goblet cells ( Fig. 1D ). When present, all these cell types diffusely populate the surface epithelium in a continuous manner, whereas goblet cells are usually singly dispersed in a background of foveolar epithelium.
Sialomucins and sulfomucins present in goblet cells are acidic, and, thus, they show positivity with histochemical stains such as Alcian blue (pH 2.5) and highiron diamine. High-iron diamine was once used to distinguish subtypes of incomplete intestinal metaplasia with a greater cancer risk, although this practice has fallen out of favor, and, as a result, high-iron diamine is infrequently used in the modern era. 2 However, widespread use of other histochemical stains persists today. Double stains for Alcian blue and periodic acid-Schiff (PAS) nicely highlight the goblet cells of Barrett esophagus; acid mucin-containing goblet cells are intensely blue with Alcian blue, whereas neutral mucins are Alcian blue negative but show magenta staining with PAS ( Fig. 2A) .
Unfortunately, the specificity of Alcian blue for goblet cells is generally low, particular with respect to distinguishing goblet cells from their morphologic mimics. Alcian blue can stain small amounts of acid mucin present in pseudogoblet cells, columnar blues, normal-appearing nongoblet columnar cells, and mucosal/submucosal glands in the esophagus (Figs. 2B-D). [3] [4] [5] Johnson and colleagues evaluated 199 esophageal biopsy samples with Alcian blue and found that this marker detected goblet cells with similar sensitivity (100%), but lower specificity (90%), compared with H&E, owing to false-positive staining of esophageal mucus glands and columnar blues. The positive predictive value of Alcian blue staining for goblet cell detection was only 72% in that study. 6 Indeed, there are no published data demonstrating superiority of any histochemical stains compared with H&E for detection of goblet cells and distinction from nongoblet epithelium.
The value of immunohistochemical markers in establishing a diagnosis of Barrett esophagus has also been investigated; CDX2, MUC2, MUC1, 45M1, and DAS1 all stain goblet cells, although none is entirely specific. CDX2 is a caudal homeobox transcription factor crucial to development of normal and metaplastic intestinal epithelial cells. One of its functions is regulation of MUC2, a mucin core peptide commonly expressed in Barrett-associated intestinal metaplasia. Both of these markers highlight goblet cells in esophageal biopsy samples ( Fig. 2E ). Phillips et al 7 used Alcian blue/PAS and CDX2 stains to evaluate 13 equivocal biopsy samples with foci suspicious for goblet cells and 49 samples that were clearly negative for intestinal metaplasia in H&E-stained sections. All 13 equivocal cases and 71% of negative controls showed Alcian blue positivity, whereas CDX2 stained 77% and 20% of cases and controls, respectively, leading them to conclude that CDX2 is superior to Alcian blue in the assessment of biopsy samples from patients with suspected Barrett esophagus. Others have found MUC2 to show superior sensitivity and specificity for goblet cells compared with both Alcian blue and CDX2, although its specificity is less than that of H&E. 8 Zhang et al 9 showed that esophageal brushings from patients with intestinal metaplasia in biopsy samples were uniformly positive for hepatocyte paraffin 1 (HepPar1), whereas those with only cardiac-type mucosa in the distal esophagus lacked HepPar1 immunoexpression. Jeung et al 10 showed frequent HepPar1 staining of goblet and nongoblet epithelia of patients with Barrett esophagus, leading the authors to speculate that HepPar1 expression may precede the appearance of goblet cells.
Some authors have suggested that staining of nongoblet columnar cells for Alcian blue, CDX2, and/or MUC2 may be relevant to the evaluation of patients with suspected Barrett esophagus ( Fig. 2F ). Chen et al 11 studied the histochemical properties of nongoblet columnar cells in patients with (n = 32) and without (n = 107) goblet cells in the esophagus. They found Alcian blue staining of nongoblet columnar epithelia in 88% of patients who had goblet cells elsewhere in the esophagus compared with 29% of those without goblet cells (P = 0.001). Groisman et al 12 evaluated samples from 90 patients with Barrett esophagus and found that nuclear CDX2 expression was uniformly present in goblet cells and adjacent nongoblet columnar cells, compared with only 38% of nongoblet epithelium in cases without goblet cells. Hahn et al 13 evaluated MUC2 staining in nongoblet epithelia of the columnar-lined esophagus and found a complete absence of MUC2 staining in 30 biopsy samples that lacked goblet cells, whereas 50/59 (85%) samples showed MUC2 staining in nongoblet columnar epithelium adjacent to goblet cells. The same study also showed significantly higher expression of other intestinal markers, including CDX2 (98%), villin (95%), and DAS1 (90%), in nongoblet epithelia of patients with goblet cells compared with samples that lacked goblet cells (43%, 17%, and 30%, respectively). Finally, McIntire et al 14 evaluated mucosal biopsy samples from 50 patients with, FIGURE 1. Goblet cells contain large cytoplasmic vacuoles of blue mucin that compress the nucleus (arrow) and cytoplasmic membranes of adjacent cells. Background foveolar epithelial cells contain an apical cap of neutral mucin (A). Pseudogoblet cells are distended by cytoplasmic mucin. Unlike goblet cells, however, they are pink owing to an abundance of neutral mucin and are associated with similar-appearing foveolar epithelial cells. Note the granulation tissue type reaction in the lamina propria of this inflamed sample (B). Columnar blues may be detected in deep glands or on the mucosal surface. Although these cells contain slightly acidic mucin that imparts a faint blue hue to the cytoplasm, they are similar in size and shape to background foveolar cells (C). Multilayered epithelium comprises immature squamoid cells subjacent to slightly distended columnar cells that contain acidic mucin (D). and 50 patients without, goblet cells in the columnar-lined esophagus, and found that 78% of patients with goblet cells had MUC2 staining in nongoblet columnar epithelium compared with only 4% of patients without goblet cells. These intriguing data imply that histochemical and/or immunohistochemical evidence of intestinal metaplasia may precede development of goblet cells in the columnar-lined esophagus. However, the relationships between staining properties of nongoblet epithelia and dysplasia and/or cancer risk have not been established. Younes and colleagues prospectively evaluated esophageal samples from 56 patients with goblet cells and 12 that contained columnar cells-simulating goblet cells. Thirty-eight percent of patients with intestinal metaplasia progressed to dysplasia, whereas only 8% of those with goblet cell mimics developed dysplasia during a 6-year follow-up interval. Alcian blue positivity was not associated with an increased risk of dysplasia development among patients who lacked goblet cells in their esophageal samples. 5 These data indicate that several histochemical and immunohistochemical markers show high sensitivity for goblet cells and can improve their detection. Unfortunately, these stains can decorate nongoblet columnar epithelium, so the staining reaction alone is not reliable in establishing a diagnosis of Barrett esophagus. Some data suggest that their expression in nongoblet epithelia is more common among patients who also have goblet cells in the esophagus, raising the possibility that these markers can identify patients at risk for intestinal metaplasia, although prospective data supporting this relationship are lacking. On the basis of the literature, we conclude that ancillary stains lack sufficient specificity for goblet cells and should not be relied upon to establish a diagnosis of Barrett esophagus.
USE OF ANCILLARY STAINS TO DISTINGUISH BARRETT ESOPHAGUS FROM INTESTINAL METAPLASIA OF THE GASTRIC CARDIA
The gastroesophageal junction is the point at which the esophageal mucosa meets the tips of the gastric rugal folds, although its precise location may be difficult to ascertain in patients with gastroesophageal reflux disease or hiatal hernias. Goblet cells are detected in approximately 10% of patients with a normal gastroesophageal junction, and 30% of those with an irregular squamocolumnar junction. In the latter situation, it can be difficult to determine whether the presence of goblet cells in a mucosal biopsy sample reflects Barrett esophagus or intestinal metaplasia of the gastric cardia. This distinction is clinically important because the latter poses a negligible cancer risk and does not currently require endoscopic surveillance, whereas the cancer risk of intestinal metaplasia in the distal esophagus is likely greater. 15 Features that suggest Barrett esophagus, rather than intestinal metaplasia of the proximal stomach, include detection of goblet cells in glands subjacent to squamous epithelium, intestinal metaplasia in superficial epithelium, and the presence of esophageal glands or ducts under glandular epithelium. 16 Some authors have proposed a battery of immunohistochemical stains to distinguish intestinal metaplasia of the esophagus from that of the stomach: CK7, CK20, MUC1, MUC2, MUC6, HepPar1, MUC5AC, and DAS1 have all been investigated. Ormsby and colleagues found that Barrett esophagus showed a characteristic pattern of CK7/CK20 staining, namely diffuse CK7 staining in superficial and deep glands combined with band-like CK20 staining of surface epithelium. In their hands, this pattern showed high sensitivity (97%) and specificity (100%) for intestinal metaplasia of the esophagus, whereas intestinal metaplasia of the gastric cardia showed either patchy CK7 and CK20 staining, or diffuse CK20 immunoexpression without CK7 staining. 17 Unfortunately, subsequent studies failed to confirm the diagnostic value of a "Barrett pattern" of CK7/CK20 staining. Rather, several different groups found this distribution of CK7/CK20 staining to be common among patients with intestinal metaplasia of the tubular esophagus, as well as intestinal metaplasia on the gastric side of the gastroesophageal junction, but infrequent in intestinal metaplasia of the distal stomach. [18] [19] [20] For example, De-Meester et al 21 observed the Barrett pattern of CK7/ CK20 staining in 100% of Barrett esophagus cases as well as 78% of samples from the cardia that showed intestinal metaplasia. Glickman and colleagues added DAS1 and MUC5AC, a gastric mucin protein, to the CK7/20 immunostain panel in an attempt to distinguish intestinal metaplasia in the esophagus from that at the gastroesophageal junction. They found no significant differences with respect to any marker: 89% to 100% of cases in both groups stained for DAS1 and MUC5AC or showed the Barrett pattern of CK7/CK20 expression. 22 Shearer and colleagues hypothesized that CK7/CK20 staining patterns may be related to gastroesophageal reflux disease rather than location of intestinal metaplasia. They evaluated CK7/CK20 staining in 80 cases of long-segment or shortsegment Barrett esophagus (n = 46) and intestinal metaplasia near the gastroesophageal junction (n = 34) and correlated the results with 24-hour pH monitoring. They found that the Barrett pattern was present in all patients with abnormal pH studies, as well as those individuals with long-segment Barrett esophagus, compared with only 67% of patients with less extensive intestinal metaplasia and normal pH monitoring results. 23 Distinguishing between intestinal metaplasia of the esophagus and gastric cardia is clinically important with respect to cancer risk and clinical surveillance. Histologic landmarks may be helpful in localizing the site of a biopsy, but they are often absent in superficial samples obtained from near the gastroesophageal junction. Unfortunately, attempts to determine the site of intestinal metaplasia using immunohistochemistry have been largely unsuccessful owing to a high prevalence of goblet cell staining in both the distal esophagus and proximal stomach. We suggest use of descriptive terminology, such as "cardiac-type mucosa with, or without, intestinal metaplasia" when the origin of a biopsy sample is not clear. This approach avoids overdiagnosis of Barrett esophagus and alerts clinicians to correlate the histologic findings with their endoscopic impressions.
USE OF ANCILLARY STAINS IN THE EVALUATION OF BARRETT ESOPHAGUS-RELATED DYSPLASIA
Barrett esophagus is a genetically unstable epithelium at risk for accumulation of molecular alterations that lead to progressive dysplasia and carcinoma, the latter of which develops at a rate of 0.2% to 0.5% per year. [24] [25] [26] Glandular dysplasia is the most important risk factor for cancer development, and, thus, it is incumbent on pathologists to appropriately classify biopsy samples from patients with Barrett esophagus. Unfortunately, inflammatory and reactive changes can hamper dysplasia detection and result in considerable interobserver varia-bility. In fact, data from one study showed that a panel of 12 pathologists failed to reach a majority diagnosis in nearly one third of cases when assessing dysplasia in challenging biopsy samples from patients with Barrett esophagus. 27 For this reason, there is considerable interest in developing biomarkers to aid the diagnosis of dysplasia and identify those patients at increased risk for neoplastic progression.
Glandular dysplasia and adenocarcinoma of the esophagus are characterized by aneuploidy, cytogenetic aberrations, DNA methylation, and loss of heterozygosity (LOH), often affecting CDKN2A, TP53, CMYC, EGFR, and erbB-2. Similar changes can also be detected at lower levels in nondysplastic Barrett esophagus. Thus, biomarkers have been used in patients with established Barrett esophagus for 2 purposes: distinguishing glandular dysplasia from non-neoplastic inflammatory mimics and predicting progression risk among patients undergoing surveillance. Immunohistochemical stains for AMACR and p53 are commonly used to evaluate samples from patients with Barrett esophagus for dysplasia. Nondysplastic Barrett esophagus is usually negative for AMACR, whereas foci of high-grade dysplasia (A) typically show strong, diffuse cytoplasmic staining (B). Unfortunately, both AMACR and p53 can stain non-neoplastic, regenerative epithelium in Barrett esophagus. This biopsy sample was obtained from an area adjacent to an ulcer; the surface shows slight nuclear enlargement with mucin depletion and infiltration by neutrophils that, at most, may be considered indefinite for dysplasia (C). However, the cells show strong, diffuse p53 immunostaining (D).
Several immunohistochemical stains may be of value in evaluating patients with Barrett esophagus for dysplasia. Two of these have emerged at the forefront of clinical use: a-methylacyl-CoA racemase (AMACR) and p53. Both markers show increased extent and intensity of staining with progressive degrees of dysplasia (Figs. 3A-D). Dorer and Odze 28 evaluated Barrett esophagus and associated neoplasia for expression of AMACR and found a progressive increase in extent and intensity of AMACR positivity in nondysplastic Barrett esophagus (0%) compared with low-grade dysplasia (38%), highgrade dysplasia (81%), and adenocarcinoma (72%). Lisovsky et al 29 reported no AMACR staining in biopsy samples with reactive atypia, compared with 11% of lowgrade dysplasias, 64% of high-grade dysplasias, and 75% of adenocarcinomas. However, other data suggest that the clinical value of this marker is limited by low sensitivity and specificity. Kastelein and colleagues evaluated samples from 635 patients with Barrett esophagus and found that 3% of cases negative for dysplasia showed strong AMACR staining, compared with only 10% and 27% of low-grade and high-grade dysplasias, respectively. Unfortunately, 46% of cases negative for dysplasia showed mild staining of glandular epithelium; any degree of AMACR staining was 67% sensitive and 50% specific for high-grade dysplasia/adenocarcinoma. 30 Some authors have evaluated the utility of AMACR positivity in the classification of cases deemed indefinite for dysplasia based on morphologic assessment. Sonwalker et al 31 studied 41 cases histologically classified as indefinite for dysplasia and found AMACR staining in 4 of 6 (67%) samples from patients who later developed dysplasia or carcinoma, compared with only 4 of 35 (11%) cases that did not progress to a higher-grade lesion (positive and negative predictive values of 44% and 92%, respectively). In the previously cited study of Kastelein and colleagues, the authors correlated AMACR expression in nondysplastic Barrett esophagus or low-grade dysplasia with neoplastic progression to high-grade dysplasia or carcinoma. Strong AMACR staining was present in only 10% of samples from patients who progressed to a higher-grade lesion, compared with 4% of biopsies from patients with stable disease (positive predictive value: 22%; and negative predictive value: 91%). 30 Mutations in TP53 lead to aberrant p53 staining that, depending on the type of molecular alteration, may be increased or completely lacking. Abnormal p53 immunostaining is usually present in high-grade dysplasia and adenocarcinoma, but it can also be detected in samples that are negative for, or show low-grade, dysplasia. Kastelein and colleagues evaluated p53 immunohistochemical staining patterns in esophageal biopsy samples from 635 patients with Barrett esophagus and clinical follow-up. They found aberrant p53 staining in 11% of biopsy samples without dysplasia, 38% of cases with low-grade dysplasia, 83% of cases with high-grade dysplasia, and 100% of adenocarcinomas. 32 The high frequency of p53 staining among cytologically malignant epithelial cell proliferations suggests that this marker may be used to confirm a mor-phologic diagnosis of high-grade dysplasia or adenocarcinoma. Indeed, Kaye et al 33 found that adding p53 immunostains to histologic evaluation decreased interobserver variability with respect to dysplasia classification and increased the predictive value of histologic diagnoses.
Data from several studies suggest that the presence, and type, of aberrant p53 staining in low-grade dysplasia may predict an increased likelihood for progression to a higher-grade lesion. Skacel et al 34 performed p53 immunohistochemistry on 16 esophageal biopsy specimens originally diagnosed with low-grade dysplasia and found that overexpression was 88% sensitive and 75% specific for progression to high-grade dysplasia or carcinoma. Murray et al 35 detected increased p53 expression in 32% of Barrett esophagus patients who ultimately developed high-grade dysplasia or carcinoma compared with 12% of controls. Weston et al 36 reported p53 positivity to be 60% sensitive and 84% specific for disease progression among 48 patients with low-grade dysplasia, although the range of positive cells (8% to 58%) in patients who progressed to a more advanced lesion overlapped considerably with that of patients who did not (17% to 66%). Kastelein and colleagues compared the predictive value of loss of p53 staining with that of overexpression in 49 patients with Barrett esophagus and low-grade dysplasia with disease progression compared with 586 controls. Only 5% of study cases showed loss of p53, but it conferred a 2-fold risk for high-grade dysplasia or carcinoma compared with p53 overexpression and a 3fold risk over a histologic diagnosis of low-grade dysplasia alone. 32 These results suggest that, although p53 immunostains have a limited role in distinguishing between low-grade dysplasia and reactive cytologic atypia, they may facilitate risk stratification of patients with low-grade dysplasia. The positive predictive value for disease progression increases from 15% for a histologic diagnosis of low-grade dysplasia alone to 33% when combined with aberrant p53 immunohistochemistry. 32 Given the available data, neither AMACR nor p53 is sufficiently sensitive or specific to be clinically useful in detection and classification of Barrett-related dysplasia. Although most high-grade dysplasias and invasive adenocarcinomas show strong and diffuse staining for 1 or both markers, an absence of staining occurs approximately 20% of the time. In addition, non-neoplastic epithelia often show staining that can be strong and diffuse, especially when mucosae are inflamed or ulcerated. However, well-designed future studies may demonstrate a role for AMACR and/or p53 immunohistochemistry in assessing risk of progression among patients with lowgrade dysplasia.
among patients with Barrett esophagus. Flow and image cytometry are 2 related techniques that measure cellular DNA content. Reid et al 37 used flow cytometry to evaluate samples of nondysplastic Barrett esophagus for aneuploidy and tetraploidy and correlated their findings with subsequent development of adenocarcinoma. They found that the presence of aneuploidy, tetraploidy, or both was a reasonable marker of cancer development with overall sensitivity and specificity of 85% and 88%, respectively. Of note, patients with low-grade dysplasia and normal flow cytometric studies did not develop adenocarcinoma, whereas those who harbored abnormal DNA content had a relative risk of 19 for carcinoma development. 37 The same group later used flow cytometric purification for neoplastic cells and polymerase chain reaction (PCR) amplification of the 17p13 locus to assess LOH at TP53. They found baseline LOH at TP53 in 6% of patients with biopsy samples initially interpreted to be negative for dysplasia; 37% of patients with TP53 loss progressed to cancer compared with only 3% of those with 2 intact alleles. Fifty-one percent of patients with high-grade dysplasia and TP53 loss developed cancer within 3 years compared with only 21% of those with high-grade dysplasia and intact TP53. 38 Sikkema and colleagues combined flow cytometry with Ki-67 and p53 immunohistochemistry in the analysis of 331 patients with Barrett esophagus, including 167 biopsy specimens from patients who later developed high-grade dysplasia or adenocarcinoma and 164 control patients who did not develop progressive disease. They found that Ki-67 expression was increased in 60% of study cases compared with 35% of controls; increased Ki-67 staining was associated with a 2-fold risk of advanced neoplasia independent of the presence of low-grade dysplasia. Overexpression of p53 was found in 55% of study cases and only 5% of controls and independently conferred a 5-fold risk of advanced neoplasia development. 39 Bird-Lieberman and colleagues evaluated the utility of automated image cytometry, p53 immunohistochemistry, and immunohistochemical stains for glycan biomarkers (CA19-9, wheat germ agglutinin, Aspergillus oryzea lectin, and CD15) to predict progression of Barrett esophagus to adenocarcinoma. With the exception of CD15, abnormal expression of all markers was associated with increased risk of adenocarcinoma, although the combination of low-grade dysplasia, aneuploidy, and Aspergillus oryzea lectin expression was most predictive of outcome. 40 
Fluorescence In Situ Hybridization
Assessment of chromosomal gains or losses by fluorescence in situ hybridization (FISH) may be even more sensitive than cytometric methods for detection of abnormal DNA content in Barrett esophagus. Rygiel and colleagues evaluated 90 brush cytology samples of Barrett mucosa with image cytometry DNA analysis and FISH with pericentromeric probes to chromosomes 7 and 17 and compared the results with histologic evaluation of concurrent biopsy samples. They found that FISH and image cytometry detected chromosomal abnormalities in 41% and 22% of cases, respectively; 13% of nondys-plastic Barrett esophagus showed gains of chromosomes 7 and/or 17 by FISH. Overall, FISH was 62% sensitive for dysplasia detection compared with histologic evaluation alone, whereas the sensitivity of image cytometry (35%) was substantially lower. 41 Given the high frequency of TP53, CDKN2A, and other alterations in Barrett-related neoplasia, it is not surprising that the diagnostic utility of several FISH probes has been assessed in patients with Barrett esophagus. Fahmy and colleagues evaluated brush cytology specimens from 40 patients with Barrett esophagus and/ or related neoplasia. They used FISH to assess losses at 17p13 (TP53) and 9p21 (CDKN2A) in conjunction with gains on chromosomes 6, 7, 11, and 12 and found either loss of TP53 or chromosomal gains in 19 of 21 (90%) patients with advanced neoplasia, whereas all cases without dysplasia were diploid with normal TP53 copy numbers. Loss of CDKN2A was more common among patients with dysplasia (81%), but it was also frequently observed among those without dysplasia (47%), thereby limiting the value of this marker in disease stratification. 42 Rygiel and colleagues used FISH probes for EGFR (7p12), CMYC (8q24.12), and 20q13.2 to analyze brush cytology specimens from 99 patients with Barrett esophagus or Barrett-related neoplasia and concomitant mucosal biopsy samples. They found low frequency amplification in nondysplastic Barrett esophagus but detected amplification of at least 1 locus in 14% of samples showing high-grade dysplasia and 50% of adenocarcinomas. 43 Several FISH panels are commercially available. Perhaps the most extensively studied are 4-probe panels that include CDKN2A, CMYC, erbB-2, and 20q13.2. Allan et al 44 utilized this panel in 20 cases of Barrett esophagus and found significant associations between dysplasia of any grade and increased probe signals for erbB-2, CMYC, and 20q13.2. Fritcher and colleagues compared the sensitivities of a 4-probe panel, digital image analysis for DNA ploidy and cytology, for detection of high-grade dysplasia and adenocarcinoma in brush cytology specimens obtained from 92 patients undergoing endoscopic surveillance for Barrett esophagus. They compared the results of these methods with histologic diagnoses made on concomitant 4-quadrant samples/centimeter of Barrett mucosae. They found that the sensitivities of cytology, digital image analysis, and FISH increased substantially from low-grade dysplasia (5%, 5%, and 50%, respectively) to high-grade dysplasia (32%, 45%, and 82%, respectively) and adenocarcinoma (45%, 45%, and 100%, respectively). Some abnormalities by FISH, namely loss of CDKN2A, gain of CMYC, or gains at multiple loci, were highly specific (100% and 100%) and sensitive (82% and 100%) for high-grade dysplasia and adenocarcinoma, respectively. By comparison, the sensitivities of cytology and ploidy analysis were much lower, ranging from 30% to 45%. Importantly, all patients with abnormal FISH results and negative biopsy findings (ie, negative for high-grade dysplasia or adenocarcinoma) progressed to high-grade dysplasia or adenocarcinoma within 6 months of follow-up. 45 It is likely that multimodality panels, such as immunohistochemistry, FISH, and PCR, improve dysplasia detection among patients with Barrett esophagus. Davelaar et al 46 hypothesized that combining immunohistochemistry with FISH would increase the sensitivity for detection of p53 abnormalities and aid detection of neoplasia in Barrett esophagus. The authors evaluated brush cytology and tissue samples from 116 patients with Barrett esophagus, including 91 patients with long-term clinical follow-up. They found that p53 abnormalities were detected by both modalities in only 9 of 40 patients with Barrett-related neoplasia, even though all of the cases of low-grade dysplasia, high-grade dysplasia, and adenocarcinoma showed either aberrant immunohistochemical expression or loss by FISH. Detection of p53 abnormalities using a combination of FISH and immunohistochemistry was also 82% sensitive and 85% specific for disease progression among patients without dysplasia on the index biopsy. 46 
Epigenetic Alterations
Modulation of gene expression by increased or decreased methylation of promoter region CpG islands contributes to Barrett-related neoplasia; hypermethylation of ESR1, MYOD1, and CDKN2A occurs early in nondysplastic Barrett mucosa and may be associated with disease progression. 47 Shulmann et al 48 used real-time methylation-specific PCR to evaluate 170 cases of Barrett esophagus/Barrett-related neoplasia and found that promoter methylation of CDKN2A, RUNX3, and HPP1 was independently predictive of progression to high-grade dysplasia or adenocarcinoma. In a subsequent paper, the same group developed a risk stratification model based on a combination of CDKN2A, RUNX3, and HPP1 methylation, length of Barrett esophagus, and presence of lowgrade dysplasia in biopsy specimens. Using these criteria, they were able to stratify 62 patients with Barrett esophagus into low-risk, intermediate-risk, and high-risk groups, which correlated well with ultimate outcome (stable disease vs. progression to high-grade dysplasia or carcinoma). Of note, the number of methylated genes was the most powerful predictor of outcome in that study. 49 Jin and colleagues validated the accuracy of a panel of 8 methylation biomarkers (p16, RUNX3, HPP1, NELL1, TAC1, SST, AKAP12, CDH13) in predicting neoplastic progression. They retrospectively evaluated a cohort of 50 patients with Barrett esophagus who developed high-grade dysplasia or adenocarcinoma and found that, when combined with patient age, the panel was 80% sensitive and 72% specific in predicting disease progression over a 4-year interval. 50 Alvi and colleagues used whole genome amplification followed by methylation-specific PCR on 22 samples of Barrett esophagus and 24 esophageal adenocarcinomas. They found that 23% of 51 genes in their platform showed statistically different levels of hypermethylation or hypomethylation between the 2 groups. A 4-gene panel (SLC22A18, PIGR, GJA12, RIN2) best distinguished nondysplastic Barrett mucosa from dysplasia and adenocarcinoma with 94% sensitivity and 97% specificity. 51 Interestingly, the markers deemed most useful by this group were not the same as those identified by Jin and colleagues, underscoring the experimental nature of these assays in the current era of risk assessment for patients with Barrett esophagus.
Future Directions
High resolution endoscopy coupled with any one of a number of advanced endoscopic techniques, such as chromoendoscopy, narrow band imaging, confocal laser endomicroscopy, and autofluorescence imaging (AFI), allows endoscopists to detect subtle mucosal abnormalities and perform targeted biopsies, potentially eliminating a "need" for random, 4-quadrant mucosal biopsy samples obtained at regular intervals throughout Barrett esophagus. Recently, di Pietro and colleagues compared use of a biomarker panel performed on a limited number of AFI-directed biopsies with standard surveillance protocols in detecting Barrettrelated neoplasia. They found that aneuploidy and abnormal p53 and cyclin A immunohistochemistry were more common in samples from AFI-positive mucosa. The overall sensitivity and specificity of targeted sampling coupled with a biomarker panel were comparable (96% and 89%, respectively) to standard biopsy protocols but required an average of 10 fewer specimens per patient. 52 It is likely that combined use of advanced endoscopic techniques with appropriate biomarker panels could reduce the number of biopsies needed to detect dysplasia in Barrett esophagus or even stratify patients with nondysplastic Barrett esophagus for surveillance depending on the presence or absence of molecular alterations.
CONCLUSIONS
There is an undeniable need for novel diagnostic approaches to the evaluation and risk stratification of patients with Barrett esophagus. Unfortunately, currently available ancillary techniques, including histochemical and immunohistochemical markers, have little to offer over routine H&E assessment, because they lack sufficient specificity for detection of Barrett esophagus and dysplasia classification. However, alterations in TP53 and p53 immunohistochemistry are promising markers; they have potential to improve diagnostic accuracy and interobserver agreement when high-grade dysplasia is a consideration and also have predictive value when abnormal in patients with low-grade dysplasia or nondysplastic Barrett esophagus. Molecular techniques, such as flow cytometry and FISH, may also prove valuable in identifying patients with nondysplastic Barrett esophagus who are at risk for disease progression. Unfortunately, most studies to date are retrospective in nature and, thus, prospective data establishing their added value are needed before their use is routinely employed in daily practice. It is likely that ancillary techniques such as those described herein will supplement pathologic assessment of Barrett esophagus in the future, particularly as these tests become more affordable and readily accessible.
